Izabella Pokorski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Izabella Pokorski has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Jan Copeland
National Cannabis Prevention & Information Centre, University of New South Wales, Medicine, Sydney, New South Wales 2052, Australia
1 shared publicationMarin Weltman
Western Sydney Local Health District, New South Wales Health Department, New South Wales 5041, Australia
1 shared publicationNghi Phung
Western Sydney Local Health District, New South Wales Health Department, New South Wales 5041, Australia
1 shared publicationNicole Clement
National Cannabis Prevention & Information Centre, University of New South Wales, Medicine, Sydney, New South Wales 2052, Australia
1 shared publication- Shanlin Fu
University of Technology Sydney
1 shared publication
Latest Publications
- 21 July 2017
- Published by Taylor & Francis in Future Neurology
- Vol. 12 (3) , 133-140
Cannabidiol in the Management of In-Patient Cannabis Withdrawal: Clinical Case Series
Aim: To assess the feasibility of the use of cannabidiol (CBD) for the management of cannabis withdrawal. Patients & methods: Eight participants were admitted to an in-patient detoxification facility for a 7-day open-label trial of CBD. Five participants received 600 mg of CBD and three participants received 1200 mg of CBD. Participants returned for a 28-day follow-up interview. Results & conclusion: CBD was well tolerated by all participants. Five completed the full treatment period and abstinence was maintained by four participants at day 28 follow-up. All those receiving the higher dose completed treatment and achieved abstinence at follow-up. This pilot study suggests that further exploration of CBD as a pharmacological adjunctive therapy for cannabis withdrawal and dependence is warranted. Registration ACTRN1261400024866.
- 21 July 2017
- Published by Taylor & Francis in Future Neurology
- Vol. 12 (3) , 133-140
Cannabidiol in the Management of In-Patient Cannabis Withdrawal: Clinical Case Series
Aim: To assess the feasibility of the use of cannabidiol (CBD) for the management of cannabis withdrawal. Patients & methods: Eight participants were admitted to an in-patient detoxification facility for a 7-day open-label trial of CBD. Five participants received 600 mg of CBD and three participants received 1200 mg of CBD. Participants returned for a 28-day follow-up interview. Results & conclusion: CBD was well tolerated by all participants. Five completed the full treatment period and abstinence was maintained by four participants at day 28 follow-up. All those receiving the higher dose completed treatment and achieved abstinence at follow-up. This pilot study suggests that further exploration of CBD as a pharmacological adjunctive therapy for cannabis withdrawal and dependence is warranted. Registration ACTRN1261400024866.